ERBB2 and non-small cell lung carcinoma: Moreover, in the NCT04144569 phase II study, 30 patients with HER2 insertion mutation-positive advanced NSCLC will receive a PD-1 inhibitor plus pyrotinib after failure of first-line chemotherapy.